SRR1417827
GTEX
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- GTEX
- cancer_type_detailed
- —
- subtype
- —
- cancer_type
- GTEX
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- KRAS_SIGNALING_DN+0.442
- PANCREAS_BETA_CELLS+0.382
- MYOGENESIS+0.345
- HEDGEHOG_SIGNALING+0.311
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.230
- APICAL_SURFACE+0.226
- SPERMATOGENESIS+0.185
- UV_RESPONSE_DN+0.175
- APICAL_JUNCTION+0.173
- ESTROGEN_RESPONSE_EARLY+0.163
Top 10 suppressed
- INTERFERON_ALPHA_RESPONSE-0.533
- MYC_TARGETS_V1-0.519
- PROTEIN_SECRETION-0.451
- E2F_TARGETS-0.433
- INTERFERON_GAMMA_RESPONSE-0.430
- MYC_TARGETS_V2-0.406
- DNA_REPAIR-0.401
- UNFOLDED_PROTEIN_RESPONSE-0.375
- G2M_CHECKPOINT-0.374
- MTORC1_SIGNALING-0.333
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR1323043 | GTEX | — | 0.964 |
| 2 | SRR1475168 | GTEX | — | 0.955 |
| 3 | SRR1314958 | GTEX | — | 0.942 |
| 4 | SRR603333 | GTEX | — | 0.935 |
| 5 | SRR1341277 | GTEX | — | 0.930 |
| 6 | SRR1337864 | GTEX | — | 0.928 |
| 7 | SRR1487321 | GTEX | — | 0.926 |
| 8 | BS_MF47B9ZW | Ganglioglioma | — | 0.922 |
| 9 | SRR1418127 | GTEX | — | 0.922 |
| 10 | SRR1331751 | GTEX | — | 0.922 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 14 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| KRAS_SIGNALING_DN | 0.442 | Remibrutinib | — uncovered |
| PANCREAS_BETA_CELLS | 0.382 | Cobimetinib | — uncovered |
| MYOGENESIS | 0.345 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.311 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.230 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.226 | Temsirolimus | — uncovered |
| SPERMATOGENESIS | 0.185 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.175 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.173 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.163 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.144 | Idelalisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.101 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.078 | Inavolisib | — uncovered |
| COAGULATION | 0.030 | Binimetinib | — uncovered |